2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161965
    MK-3168 (12C) 1242441-26-4 98%
    MK-3168 (12C) is a FAAH inhibitor with IC50 values of 1.0, 5.5, 1.7 nM for human, rhesus, rat, respectively. MK-3168 shows good brain uptake and FAAH-specific signal. 11C MK-3168 can be used as FAAH PET tracer.
    MK-3168 (12C)
  • HY-162050
    8AQ−Cu−5Iu 98%
    8AQ?Cu?5Iu is an activator of SIRT1. 8AQ?Cu?5Iu exhibits neuroprotective effects by modulating the SIRT1/3-FOXO3a signaling pathway. 8AQ?Cu?5Iu can used in study attenuating neurodegenerative diseases.
    8AQ−Cu−5Iu
  • HY-162070
    CCK antagonist 1 742116-45-6 99.96%
    CCK antagonist 1 (compound 3d) is a CCK antagonist with IC50s of 1.1 μM and 4 μM for CCK1 and CCK2, respectively. CCK antagonist 1 can be used for research of cancer and mental disease.
    CCK antagonist 1
  • HY-162107
    Dyrk1A-IN-6 98%
    Dyrk1A-IN-6 (compound 7cc) is an EGCG-like non-competitive inhibitor of DYRK1A. Dyrk1A-IN-6 can be used to alleviate cognitive defects in Down syndrome models.
    Dyrk1A-IN-6
  • HY-16216R
    Gabapentin enacarbil (Standard) 478296-72-9 98%
    Gabapentin enacarbil (Standard) is the analytical standard of Gabapentin enacarbil. This product is intended for research and analytical applications. Gabapentin enacarbil (XP-13512) is a prodrug of Gabapentin (HY-A0057) designed to be absorbed throughout the intestine by high-capacity nutrient transporters. Gabapentin is a potent, orally active P/Q type Ca2+ channel blocker. Gabapentin enacarbil can be used for the study of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).
    Gabapentin enacarbil (Standard)
  • HY-162597
    Dyrk1A-IN-9 98%
    Dyrk1A-IN-9 (Compound L9) is a moderately active DYRK1A inhibitor (IC50: 1.67 μM). L9 shows neuroprotective activity by regulating the expression of Aβ and phosphorylation of Tau protein. Dyrk1A-IN-9 can be used for research of Alzheimer's disease.
    Dyrk1A-IN-9
  • HY-162872
    NBI-35965 268546-19-6 98%
    NBI-35965 is an antagonist of corticotropin-releasing factor receptor 1 (CRF-R1). NBI-35965 can be used in nervous system related research.
    NBI-35965
  • HY-163096
    GPR88 agonist 3 2963597-44-4 98%
    GPR88 agonist 3 (compound 20) is a GPR88 agonist 3, with an EC50 of 204 nM. GPR88 agonist 3 can be used for psychiatric and neurodegenerative disorders research.
    GPR88 agonist 3
  • HY-163138
    DAT-IN-1 3033213-24-7 98%
    DAT-IN-1 (Coumpound 12b) is an atypical DAT inhibitor with a Ki of 8.37 nM. DAT-IN-1 can be used in the study of psychostimulant use disorder (PSUD).
    DAT-IN-1
  • HY-16346R
    Netupitant (Standard) 290297-26-6
    Netupitant (Standard) is the analytical standard of Netupitant. This product is intended for research and analytical applications. Netupitant (CID-6451149) is a highly potent, selective and orally active neurokinin-1 (NK1) receptor antagonist with a Ki of 0.95 nM for hNK1 in CHO cells. Netupitant has antiemetic affect.
    Netupitant (Standard)
  • HY-163662
    AE027 1011351-65-7 98%
    AE027 is a potent inhibitor against both WT and resistant mutation F348Y AChE with the IC50 values of 10 and 43 μM, respectively.
    AE027
  • HY-16397R
    Phenformin (Standard) 114-86-3 98%
    Phenformin (Phenethylbiguanide) (Standard) is the analytical standard of Phenformin (HY-16397). This product is intended for research and analytical applications. Phenformin (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin inhibits cancer stem cells (CSCs) and possesses potent antitumor potential.
    Phenformin (Standard)
  • HY-164009
    Teniloxazine 62473-79-4 98%
    Teniloxazine is an inhibitor for norepinephrine neuronal reuptake and an weak inhibitor for reuptake of Serotonin (HY-B1473A) and Dopamine (HY-B0451). Teniloxazine exhibits antidepressant, antihypoxic and anti-amnestic properties without anticholinergic, sedative, and cardiovascular adverse effects.
    Teniloxazine
  • HY-164011
    Alaproclate 60719-82-6 98%
    Alaproclate is an inhibitor for serotonin (5-HT) reuptake. Alaproclate affects mechanisms that related to cued navigation performance such as sensory, sensorimotor, or motivational factors, impairs spatial navigation ability of rats.
    Alaproclate
  • HY-164264
    Caged MK801 217176-91-5 98%
    Caged MK801 (cMK801) is a selective, non-competitive, irreversible NMDA receptor open-channel blocker. NVOC cages are neuro pharmocologically compatible.
    Caged MK801
  • HY-164412
    Phosphatidylcholine (C18:2,C20:4) 85082-02-6 98%
    Phosphatidylcholine (C18:2,C20:4) is a phosphatidylcholine species containing linoleic acid (C18:2) and arachidonic acid (C20:4) as fatty acid components, that can be isolated from egg yolk, red blood cell membranes of rat, rabbit, human, and dog. Phosphatidylcholine (C18:2,C20:4) can be used as a biomarker for the research of Alzheimer's disease.
    Phosphatidylcholine (C18:2,C20:4)
  • HY-164504
    NRMA-10 2375659-17-7
    NRMA-10, an amide prodrug, is a brain-penetrant nuclear receptor modulator. NRMA-10 increases brain expression of Adam10. NRMA-10 preferres distribution to the CNS compared to the periphery. NRMA-10 can be used for the study of central nervous system (CNS) disorders.
    NRMA-10
  • HY-164506
    NRMA-8 2375659-15-5 98%
    NRMA-8 is a brain-penetrant small molecule nuclear receptor modulator. NRMA-8 is promising for research of central nervous system disorders, including Alzheimer's disease, Parkinson's disease, demylenation disorders and glioblastomas.
    NRMA-8
  • HY-164649
    Atibeprone 153420-96-3 98%
    Atibeprone (Lu 53439) is a selective MAO-B inhibitor. Atibeprone has antidepressant activity.
    Atibeprone
  • HY-164685
    T-0156 free base 324572-92-1 98%
    T-0156 free base is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 free base specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 free base inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 free base enhances the nitric oxide (NO)/cGMP pathway.
    T-0156 free base
Cat. No. Product Name / Synonyms Application Reactivity